https://scholars.lib.ntu.edu.tw/handle/123456789/580408
標題: | Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | 作者: | Lu Y.-S. CHIUN HSU Li C.-C. Kuo S.-H. KUN-HUEI YEH CHIH-HSIN YANG CHIH-HUNG HSU Wu C.-Y. ANN-LII CHENG |
公開日期: | 2004 | 卷: | 51 | 期: | 57 | 起(迄)頁: | 815-819 | 來源出版物: | Hepato-Gastroenterology | 摘要: | Background/Aims: Our previous studies showed that high-dose tamoxifen may improve the therapeutic efficacy of doxorubicin (HTD regimen) in hepatocellular carcinoma. Interferon-α, either as a single-agent treatment or as a biochemical modulator, has also been reported to be effective in the treatment of hepatocellular carcinoma. In this study, we sought to clarify if the addition of Interferon-α2b to HTD regimen could further improve the control of advanced hepatocellular carcinoma. Methodology: Eligible patients had unresectable and non-embolizable hepatocellular carcinoma, objectively measurable tumors, adequate hemogram and major organ function, age ?75 year, and a Karnofaky performance status ?60%. The treatment included oral tamoxifen 40mg/m2, q.i.d, Day 1-7; interferon-α2b subcutaneous injection, 5MU/m2, q.d. (Day 3-5) and 3MU/m2, q.o.d. (Day 6-21); and intravenous doxorubicin 60mg/m2, Day 4, repeated every 4 weeks. Results: From May 1997 through July 2002, a total of 30 patients were enrolled, 25 of whom were eligible for assessment of response and toxicity. These included 20 men and 5 women, with a median age of 45 years. They received an average of 3.5 (range: 1-8) courses of chemotherapy. Grade 3-4 leukopenia and Grade 3-4 thrombocytopenia developed in 46.7% and 51.0% of treatment courses, respectively. Gastrointestinal toxicity was generally mild. One patient achieved a complete remission and remained disease-free at this report, with a progression-free survival of 49 months at last follow-up in September 2002. Five patients achieved a partial remission, with a median progression-free survival of 7 months. The total response rate was 24% (95% confidence interval 9.4-45.1%). Median survival for all 25 patients was 6.0 months and the 1-year survival rate was 16%. Conclusions: Combination of interferon-α2b, high-dose tamoxifen, and doxorubicin is an effective treatment for advanced hepatocellular carcinoma. However, the data does not support that addition of interferon-α2b is superior to HTD regimen alone. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-2342564423&partnerID=40&md5=f29408f2b4a1aba448bf71f940472c48 https://scholars.lib.ntu.edu.tw/handle/123456789/580408 |
ISSN: | 0172-6390 | SDG/關鍵字: | alpha2b interferon; antineoplastic agent; doxorubicin; paracetamol; recombinant alpha2b interferon; tamoxifen; adult; advanced cancer; article; cancer combination chemotherapy; cancer control; cancer regression; cancer surgery; cancer survival; clinical article; clinical trial; controlled clinical trial; controlled study; diarrhea; disease course; drug megadose; drug response; female; flu like syndrome; follow up; function test; gastrointestinal disease; hematology; human; infection; leukopenia; liver cell carcinoma; male; nausea; phase 2 clinical trial; priority journal; prognosis; stomatitis; thrombocytopenia; tumor volume; vomiting; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Tamoxifen |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。